Search Results
Dec 08, 2025, 09:00 ET Monster Energy's Joshua Van Defeats Alexandre Pantoja to Claim UFC Flyweight World Championship Title at UFC 323
unfolded with Barber relying on her dominant grappling skills to gain the upper hand on the judges' scorecards in every round. Barber defended against a body triangle in Round 1 and countered with heavy ground and pound until the end of the round.In a controversial scene in the second round, Barber
More news about: Monster Energy
Dec 08, 2025, 08:37 ET Pusan National University Study Highlights the Health Hazards of Ultrafine Particles from Small Home Appliances with Electric Heating Coils and Brushed DC Motors
aluminum, silver, and titanium. "These associated heavy metals increase the risk of cytotoxicity and inflammation when the particles enter the human body," mentioned Dr. Kim.The simulation showed that UFPs deposit mainly in the alveolar region of the lungs, and children face higher health risks
More news about: Pusan National University
Dec 08, 2025, 08:30 ET PLANET FITNESS KICKS OFF 2026 AS PRESENTING SPONSOR OF TIMES SQUARE'S NEW YEAR'S EVE CELEBRATION, EMPOWERING THE NATION TO EMBRACE FITNESS FOR ALL
self-care and personal well-being. Planet Fitness empowers individuals to fulfill their resolutions by offering a high-value experience designed for every body and fitness level, offering:Best-in-Class Equipment and Experiences: Access to strength and name-brand cardio equipment,
More news about: Planet Fitness, Inc.
Dec 08, 2025, 08:00 ET Israir Group Concludes the Best Quarter in Its History with a Net Profit of Approximately USD 35 Million, a 75% Increase, and EBITDAR of USD 46 Million
to continue investing in its fleet, in advanced technologies, and in customer service. The company is currently exploring an investment in two wide-body Airbus A330 aircraft."Contact:Lee Marie [email protected]
More news about: Israir Group
Dec 08, 2025, 08:00 ET Liberty Defense Technologies Joins NVIDIA Connect Program to Accelerate AI-Powered Threat Detection Innovations
metallic and non-metallic weapons. Liberty has also recently licensed the millimeter wave-based, High-Definition Advanced Imaging Technology (HD-AIT) body scanner and shoe scanner technologies as part of its technology portfolio. Liberty is committed to protecting communities and preserving peace of mind
More news about: Liberty Defense
Dec 08, 2025, 08:00 ET Inductive Bio Announces an Up To $21M Award to Develop AI Drug Toxicity Models that Improve Drug Safety Assessment with Leading Academic and Biopharmaceutical Organizations
millions of experiments on digital organs trained on data from human organs and organoids, enabling teams to predict how molecules will behave in the body. The most promising molecules move from the virtual lab to the wet lab in a tight feedback loop that accelerates the advancement of high-quality molecules.
More news about: Inductive Bio, Inc.
Dec 08, 2025, 08:00 ET Ramaco Resources Announces Fourth Quarter Class B Stock Dividend Details
related to the development and production of advanced carbon products and materials derived from coal. In connection with these activities, it holds a body of roughly 76 intellectual property patents, pending applications, exclusive licensing agreements and various trademarks.News and additional
More news about: Ramaco Resources, Inc.
Dec 08, 2025, 08:00 ET Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
cell-associated neurotoxicity syndrome, graft vs. host disease, transmission of infection or bone marrow/solid organ transplant rejection."The growing body of evidence supporting the efficacy and safety of tabelecleucel in treatment of people living with EBV+PTLD enhances our confidence in the potential
More news about: Pierre Fabre Pharmaceuticals
Dec 08, 2025, 07:30 ET Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
unknown, and there are no known risk factors. Some people with iMCD have elevated levels of interleukin 6 (IL-6), a cytokine that is produced in the body during inflammation and which plays a central pathological role in iMCD; IL-6 elevation may explain some of the symptoms patients experience, such as
More news about: Recordati
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory
More news about: UCB
Dec 08, 2025, 06:50 ET Manipal Hospitals Enhances Movement and Confidence Through Awareness on Movement Disorders
confidently with such conditions. Reinforcing the value of physical activity, he said, "Exercise remains the best medicine - it strengthens the body, sharpens memory, and helps the brain adapt and recover through neuroplasticity. Movement is very important as well for everyone. If the movement is
More news about: Manipal Hospitals
Dec 08, 2025, 06:01 ET Protective Clothing Market worth $15.06 billion by 2030 - Exclusive Report by MarketsandMarkets™
clothing market. The regular occurrence of devastating, highly communicable illnesses is driving the demand for biohazard suits that provide comprehensive body-level biological protection. The healthcare, research and emergency response industries demand garments which can establish a waterproof barrier against
More news about: MarketsandMarkets
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
plateau was observed for weight loss. The baseline mean body weight and body mass index (BMI) of participants were 107.3 kg and 38.6 kg/m2, respectively.80.0% of participants taking 60 mg of ASC30 once daily lost ≥5% of their body weight, compared to 4.2% with placebo; 45.0% of participants
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 03:00 ET AGIBOT Announces the Rollout of Its 5,000th Mass-Produced Humanoid Robot
general-purpose embodied robot products and an application ecosystem. Built on the foundation of robotic body and powered by the fusion of interaction, manipulation, and locomotion intelligence — "1 Robotic Body + 3 Intelligence" — AGIBOT is a leading robotics company in the industry to deliver a complete product
More news about: Agibot
Dec 08, 2025, 00:59 ET HCMCT Manipal Hospitals Delhi, India performs lifesaving heart transplant on a 54-year-old woman
She arrived at the hospital in a critical state with an extremely low ejection fraction of 15%, repeated hospitalisations, whole-body edema (swelling), severe fatigue and breathlessness that left her barely able to walk or lie down comfortably. She was on intra-aortic balloon pump
More news about: Manipal Hospitals
Dec 08, 2025, 00:52 ET HCMCT Manipal Hospitals Delhi, India performs lifesaving heart transplant on a 54-year-old woman
She arrived at the hospital in a critical state with an extremely low ejection fraction of 15%, repeated hospitalisations, whole-body edema (swelling), severe fatigue and breathlessness that left her barely able to walk or lie down comfortably. She was on intra-aortic balloon pump
More news about: Manipal Hospitals
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued innovation and have been validated
More news about: Leads Biolabs
Dec 07, 2025, 12:01 ET Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
hemophilia.About HEMGENIXHEMGENIX is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus
More news about: CSL
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles,
More news about: Orna Therapeutics
Dec 06, 2025, 11:00 ET LiberNovo Lands in Europe with Omni -- The Next-Gen Ergonomic Chair You Can Order Now
LiberNovo Omni — the next-generation dynamic ergonomic office chair designed to adapt to every micro-movement of the body. With integrated fulfillment across the US, Canada, the EU, Germany, and the UK, Omni is now in stock and ready to ship, eliminating the
More news about: LiberNovo
Dec 06, 2025, 11:00 ET LiberNovo Goes Global: New Markets & A Vision for Healthy Workspaces
illustrated how the LiberNovo Omni responds to micro-movements in real time—showing a tangible pathway toward AI-interactive ergonomics that support the body intuitively, not reactively.This moment signaled more than a presence on stage. It positioned LiberNovo at the intersection of AI × wellness
More news about: LiberNovo
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
as first relapse, the disease did not progress and no further treatment was required at 2.5 years (30 months).1 These results add to the body of clinical and real-world experience established across more than 9,000 patients treated with CARVYKTI® globally.1
More news about: Johnson & Johnson
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
transplantation. Patients had similar outcomes with chemotherapy-based conditioning versus total body irradiation, suggesting that patients who are low-risk can safely avoid the long-term side effects of total body irradiation with a chemotherapy-based regimen.In the final study, researchers found that
More news about: American Society of Hematology
Dec 06, 2025, 07:15 ET Studies Highlight Innovative Approaches to Improving Patient Care and Outcomes
Iron deficiency occurs when the body's iron stores are too low, and is the most common cause of anemia, when the body has too few red blood cells or those cells don't work properly. The body needs iron to, among other things, form hemoglobin, the component of red blood cells that carries oxygen to the
More news about: American Society of Hematology
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
experienced any late rejection or severe graft-versus-host disease (GVHD), a condition in which the transplanted donor cells attack the recipient's body.Sickle cell disease outcomes, which were assessed at a median of five years post-transplant, were also largely positive. Most patients (86%) remained
More news about: American Society of Hematology